Multi-Center Study of New Medications to Treat Vaginal Infections

NCT ID: NCT02308007

Last Updated: 2020-08-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

475 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-30

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and efficacy of terconazole/metronidazole gel in the treatment of vaginal infections

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vaginal Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Terconazole vaginal gel

One applicator full at bedtime

Group Type ACTIVE_COMPARATOR

Terconazole

Intervention Type DRUG

Metronidazole vaginal gel

One applicator full at bedtime

Group Type ACTIVE_COMPARATOR

Metronidazole

Intervention Type DRUG

Terconazole/metronidazole vaginal gel

One applicator full at bedtime

Group Type ACTIVE_COMPARATOR

Terconazole/metronidazole

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Terconazole

Intervention Type DRUG

Metronidazole

Intervention Type DRUG

Terconazole/metronidazole

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A clinical diagnosis of vaginal infection that is confirmed by laboratory testing and:
* Capable of providing written informed consent or assent
* Currently not menstruating and not anticipating menses during treatment
* If heterosexually active, subject must be post-menopausal for ≥ 1 year, surgically sterile, or practicing an acceptable form of birth control
* Negative pregnancy test
* Other criteria as identified in the protocol

Exclusion Criteria

* Other infectious causes of vulvovaginitis
* Subject has recently used, or is expected to require the concomitant use of prohibited medications/products
* Nursing mother
* Use of any investigational drug within 30 days of enrollment
* History of hypersensitivity to any ingredient/component of the formulations
* Other criteria as identified in the protocol
Minimum Eligible Age

12 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Curatek Pharmaceuticals, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert J Borgman, Ph.D.

Role: STUDY_DIRECTOR

Curatek Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alabama Clinical Therapeutics

Birmingham, Alabama, United States

Site Status

University of Alabama

Birmingham, Alabama, United States

Site Status

Precision Trials, AZ

Phoenix, Arizona, United States

Site Status

MomDoc Womens Health Research

Scottsdale, Arizona, United States

Site Status

DelSol Research

Tucson, Arizona, United States

Site Status

NEA Baptist Clinic

Jonesboro, Arkansas, United States

Site Status

Gossmont Center for Clinical Research

La Mesa, California, United States

Site Status

Genesis Center for Clinical Research

San Diego, California, United States

Site Status

Medical Center for Clinical Research

San Diego, California, United States

Site Status

Downtown Women's Health Care

Denver, Colorado, United States

Site Status

Red Rocks Ob/Gyn

Lakewood, Colorado, United States

Site Status

Women's Health CT Ob/Gyn

Bridgeport, Connecticut, United States

Site Status

Precision Clinical Research

Coral Springs, Florida, United States

Site Status

KO Clinical Research, LLC

Fort Lauderdale, Florida, United States

Site Status

Segal Institute for Clinical Research

North Miami, Florida, United States

Site Status

Discovery Clinical Research

Plantation, Florida, United States

Site Status

Comprehensive Clinical Trials, LLC

West Palm Beach, Florida, United States

Site Status

Georgia Regents University

Augusta, Georgia, United States

Site Status

Atlanta North Gynecology

Roswell, Georgia, United States

Site Status

Mount Vernon CLinical Research

Sandy Springs, Georgia, United States

Site Status

Rosemark Womens Care Specialists

Idaho Falls, Idaho, United States

Site Status

Women's Health Practice

Champaign, Illinois, United States

Site Status

Indiana University

Indianapolis, Indiana, United States

Site Status

Praetorian Pharmaceutical Research, LLC

Marrero, Louisiana, United States

Site Status

Southern Clinical Research Associates

Metairie, Louisiana, United States

Site Status

Women Under Study

New Orleans, Louisiana, United States

Site Status

Wayne State University

Detroit, Michigan, United States

Site Status

Women's Healthcare Specialists, PC

Kalamazoo, Michigan, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Women's Clinic of Lincoln

Lincoln, Nebraska, United States

Site Status

Legacy Women's Health

Las Vegas, Nevada, United States

Site Status

R. Garn Mabey Jr., MD Gynecology

Las Vegas, Nevada, United States

Site Status

Lawrence Ob/Gyn Clinical Research LLC

Lawrenceville, New Jersey, United States

Site Status

Women's Health Research Center

Plainsboro, New Jersey, United States

Site Status

Suffolk OB/GYN

Port Jefferson, New York, United States

Site Status

East Carolina Women's Center

New Bern, North Carolina, United States

Site Status

Wake Research Associates

Raleigh, North Carolina, United States

Site Status

Radiant Research

Columbus, Ohio, United States

Site Status

Complete Healthcare for Women

Columbus, Ohio, United States

Site Status

Drexel University

Philadelphia, Pennsylvania, United States

Site Status

Philapelphia Clinical Research, LLC

Philadelphia, Pennsylvania, United States

Site Status

Magee-Womens Hospital of UPMC

Pittsburgh, Pennsylvania, United States

Site Status

Magnolia Ob/Gyn Research Center

Myrtle Beach, South Carolina, United States

Site Status

James T. Martin, MD

North Charleston, South Carolina, United States

Site Status

The Jackson Clinic

Jackson, Tennessee, United States

Site Status

Discovery Clinical Trials

Dallas, Texas, United States

Site Status

Signature Gyn Services

Fort Worth, Texas, United States

Site Status

Texas Children's Hospital for Women

Houston, Texas, United States

Site Status

TMC Life Research, Inc.

Houston, Texas, United States

Site Status

Harborview Medical Center

Seattle, Washington, United States

Site Status

Women's Clinical Research Center

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MTC-001 (Trial 3)

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TOL-463 Phase 2 Study for Vaginitis
NCT02866227 COMPLETED PHASE2
Study of UC-781 Vaginal Microbicide
NCT00132444 COMPLETED PHASE1